Nivolumab

Last month, I mentioned my favorite new oxymoron — “Environmental Protection Agency” — and am concerned you might have missed it if you were on vacation ... so I raise the topic again.

The addition of nivolumab and low-dose ipilimumab to first-line chemotherapy significantly extended OS for patients with advanced non-small cell lung cancer, according to results of a prespecified interim analysis from the randomized phase 3 CheckMate -9LA trial.

BARCELONA, Spain — Nivolumab extended survival compared with chemotherapy among patients with advanced or recurrent esophageal squamous cell carcinoma regardless of PD-L1 expression, according to results of the randomized phase 3 ATTRACTION study presented at European Society for Medical Oncology Congress.

BARCELONA, Spain — Nivolumab in combination with ipilimumab conferred clinical benefit for women with recurrent or metastatic cervical cancer regardless of PD-L1 status, according to results of the randomized phase 1b/phase 2 CheckMate 358 study presented at European Society for Medical Oncology Congress.

BARCELONA, Spain — A combination of nivolumab and low-dose ipilimumab significantly improved OS compared with chemotherapy as first-line treatment for patients with advanced non-small cell lung cancer, according to results of the randomized phase 3 CheckMate 227 study presented at European Society for Medical Oncology Congress.

BARCELONA, Spain — Nivolumab did not significantly extend OS compared with sorafenib as first-line therapy for patients with advanced hepatocellular carcinoma, according to results of the randomized phase 3 CheckMate 459 trial presented at European Society for Medical Oncology Congress.

Nivolumab showed promising efficacy among women with recurrent or metastatic cervical, vaginal or vulvar cancers, according to results from the single-arm phase 1/phase 2 CheckMate 358 trial published in Journal of Clinical Oncology.

Click here to read the Cover Story, “Growing incidence of Merkel cell carcinoma draws researchers’ attention.”

BARCELONA — Nivolumab led to a fivefold improvement in OS at 5 years compared with docetaxel among patients with previously treated advanced non-small cell lung cancer, according to pooled results from the CheckMate 017 and 057 trials presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer.

BARCELONA — The combination of low-dose, weight-based ipilimumab and flat-dose nivolumab demonstrated safety and efficacy as first-line treatment for patients with stage IV non-small cell lung cancer and comorbidities that traditionally preclude them from enrolling in clinical trials, according to results of the single-arm, nonrandomized CheckMate 817 study presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer.